Novartis Pharma GmbH (release of the finished medicinal product)/Novartis Pharmaceuticals, S.A. (release of the finished medicinal product)
UkraineAll drugs from this manufacturer
-
The drug is used for the prevention of acute kidney rejection during kidney transplantation in adults and children aged 1 to 17 years.
Dosage form: powder for solution for injection/infusion
Active substance Dosage basiliximab 20 mg ATC: L04AC02